Protective Role of Maternal P.VAL158MET Catechol-O-methyltransferase Polymorphism against Early-Onset Preeclampsia and its Complications

Open access

Summary

Background: Up until now there have been contradictory data about the association between p.Val158Met catechol-O-methyltransferase (COMT) polymorphism and risk of preeclampsia (PE). The goal of this study was to assess the potential correlation between p.Val158Met COMT polymorphism and risk of early-onset PE, risk of a severe form of early-onset PE, as well as risk of small-for-gestationalage (SGA) complicating PE.

Methods: The study included 47 early-onset PE patients and 47 control cases. Forty-seven early-onset PE patients were grouped by disease severity (33 patients with a severe form and 14 patients without severe features) and secondly by size for gestational age (12 patients with appropriate-for-gestational-age (AGA) and 35 patients with SGA size). p.Val158Met polymorphism was genotyped by PCR-RFLP analysis.

Results: Allele analysis showed significant difference in COMT allele distribution between early-onset PE and control group as well as early-onset PE SGA and controls (p=0.04057 and p=0.0411 respectively). A statistically significant distribution difference between the severe form and form without severe features of early-onset PE patients was not observed (p>0.05). The highest difference observed was in the allele recessive model where COMT MetMet genotype was associated with decreased risk of early-onset PE (OR=0.281; 95%CI=0.092-0.7836) and PE complications including severe early-onset PE (OR= 0.304; 95%CI=0.086-0.944) and SGA early-onset PE (OR=0.284; 95%CI=0.081-0.874).

Conclusions: COMT may be used as a candidate gene for early-onset PE and its severe form and SGA complications.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Abalos E Cuesta C Carroli G Qureshi Z Widmer M Vogel JP et al.; WHO Multicountry Survey on Maternal and Newborn Health Research Network. Pre-eclampsia eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG 2014; 121: 14-24.

  • 2. Say L Chou D Gemmill A Tunçalp Ö Moller AB Daniels J et al. Global causes of maternal death: A WHO systematic analysis. Lancet Global Health 2014; 2: e323-33.

  • 3. Alkema L New JR Pedersen J You D all members of the UN Inter-agency Group for Child Mortality Estimation and its Technical Advisory Group. Child mortality estimation 2013: An overview of updates in estimation methods by the United Nations Inter-agency Group for child mortality estimation. PloS ONE 2014; 9: e101112.

  • 4. Cousens S Blencowe H Stanton C Chou D Ahmed S Steinhardt L et al. National regional and worldwide estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis. Lancet 2011; 377: 1319-30.

  • 5. World Health Organization. World Health Statistics 2014. New York: World Health Organization; 2014.

  • 6. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hy per - tension in Pregnancy. Obstet Gynecol 2013; 122: 1122-31.

  • 7. Roberts JM Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53-6.

  • 8. Steegers EA von Dadelszen P Duvekot JJ Pijnenborg R. Pre-eclampsia. Lancet 2010; 376: 631-44.

  • 9. Valenzuela FJ Perez-Sepulveda A Torres MJ Correa P Re petto GM Illanes SE. Pathogenesis of preeclampsia: the genetic component. J Pregnancy 2012; 2012: 632732.

  • 10. Kanasaki K Palmsten K Sugimoto H Ahmad S Hamano Y Xie L et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature 2008; 453: 1117-21.

  • 11. Liang S Liu X Fan P Liu R Zhang J He G et al. Association between Val158Met functional polymorphism in the COMT gene and risk of preeclampsia in the Chinese population. Arch Med Res 2012; 43: 154-8.

  • 12. Williams PJ Morgan L. The role of genetics in preeclampsia and potential pharmacogenomic interventions. Pharmagenomics Pers Med 2012; 5: 37-51.

  • 13. Lim JH Kim SY Kim Do J Park SY Han HW Han JY et al. Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17a in preeclampsia. Pharmacogenet Genomics 2010; 20: 605-10.

  • 14. Hill LD York TP Kusanovic JP Gomez R Eaves LJ Romero R et al. Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One 2011; 6: e16681.

  • 15. Schnettler WT Dukhovny D Wenger J Salahuddin S Ralston SJ Rana S. Cost and resource implications with serum angiogenic factor estimation in the triage of preeclampsia. BJOG 2013; 120: 1224-32.

  • 16. Statistical Office of the Republic of Serbia United Nations Children’s Fund. Multiple Indicator Cluster Survey 2010 Monitoring the situation of children and women. Belgrade: Unicef Belgrade; 2010.

  • 17. Purcell S Cherny SS Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19: 149-50.

  • 18. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria 2014; URL http://www.R-project.org/.

  • 19. Raymond D Peterson E. A Critical Review of Early-Onset and Late-Onset Preeclampsia. Obstet Gynecol Surv 2011; 66: 497-506.

  • 20. Odegard RA Vatten LJ Nilsen ST Salvesen KA Austgulen R. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96: 950-5.

  • 21. Salonen Ros H Lichtenstein P Lipworth L Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet 2000; 91: 256-60.

  • 22. Goddard KA Tromp G Romero R Olson JM Lu Q Xu Z et al. Candidate gene association study of mothers with pre-eclampsia and their infants analyzing 775 SNPs in 190 genes. Hum Hered 2007; 63: 1-16.

  • 23. Trogstad L Skrondal A Stoltenberg C Magnus P Nesheim BI Eskild A. Recurrence risk of preeclampsia in twin and singleton pregnancies. Am J Med Genet A 2004; 126: 41-5.

  • 24. Carreiras M Montagnani S Layrisse Z. Preeclampsia: a multifactorial disease resulting from the interaction of the feto-maternal HLA genotype and HCMV infection. Am J Reprod Immunol 2002; 48: 176-83.

  • 25. Zhu BT Wu KY Wang P Cai MX Conney AH. O-methylation of catechol estrogens by human placental catechol- o-methyltransferase: interindividual differences in sensitivity to heat inactivation and to inhibition by dietary polyphenols. Drug Metab Dispos 2010; 38: 1892-9.

  • 26. Zhu BT. Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab 2002; 3: 321-49.

  • 27. Berg D Sonsalla R Kuss E. Concentrations of 2-metho - xyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. Acta Endocrinol (Copenh) 1983; 103: 282-8.

  • 28. Barnea ER MacLusky NJ DeCherney AH Naftolin F. Catechol-O-methyl transferase activity in the human term placenta. Am J Perinatol 1988; 5: 121-7.

  • 29. Shield AJ Thomae BA Eckloff BW Wieben ED Wein - shilboum RM. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry 2004; 9: 151-60.

  • 30. Roten LT Fenstad MH Forsmo S Johnson MP Moses EK Austgulen R et al. A low COMT activity haplotype is associated with recurrent preeclampsia in a Norwegian population cohort (HUNT2). Mol Hum Reprod 2011; 17: 439-46.

  • 31. Wang X Zuckerman B Pearson C Kaufman G Chen C Wang G et al. Maternal cigarette smoking metabolic gene polymorphism and infant birth weight. JAMA 2002; 287: 195-202.

  • 32. Vaessen N Janssen JA Heutink P Hofman A Lamberts SW Oostra BA et al. Association between genetic variation in the gene for insulin-like growth factor-I and low birth weight. Lancet 2002; 359: 1036-7.

  • 33. Sata F Yamada H Suzuki KSaijo Y Yamada T Minakami H et al. Functional maternal catechol-O-methyl trans ferase polymorphism and fetal growth restriction. Phar ma - cogenet Genomics 2006; 16: 775-81.

  • 34. Yager JD Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996; 36: 203-32.

  • 35. Malins DC Holmes EH Polissar NL Gunselman SJ. The etiology of breast cancer: characteristic alterations in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer 1993; 71: 3036-43.

  • 36. Malins DC Polissar NL Gunselman SJ. Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc Natl Acad Sci USA 1996; 93: 2557-63.

  • 37. Scholl TO Stein TP. Oxidant damage to DNA and pregnancy outcome. J Matern Fetal Med 2001; 10: 182-5.

  • 38. Novaković I Maksimović N Pavlović A Žarković M Rovčanin B Mirković D Pekmezović T Cvetković D. Introduction to molecular genetic diagnostics. J Med Biochem 2014; 33: 3-7.

Search
Journal information
Impact Factor


IMPACT FACTOR 2018: 2,000
5-year IMPACT FACTOR: 1,075



CiteScore 2018: 1.47

SCImago Journal Rank (SJR) 2018: 0.523
Source Normalized Impact per Paper (SNIP) 2018: 0.581

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 320 236 12
PDF Downloads 137 109 5